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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a KRAS-driven cancer with a high 
incidence of metastasis and an overall poor prognosis. Previous work in a genetically 
engineered mouse model of PDAC showed glucose metabolism to be important for 
maintaining tumor growth. Multiple glycolytic enzymes, including hexokinase 2 (HK2), 
were upregulated in primary PDAC patient tumors, supporting a role for glycolysis 
in promoting human disease. HK2 was most highly expressed in PDAC metastases, 
suggesting a link between HK2 and aggressive tumor biology. In support of this we 
found HK2 expression to be associated with shorter overall survival in PDAC patients 
undergoing curative surgery. Transient and stable knockdown of HK2 in primary 
PDAC cell lines decreased lactate production, anchorage independent growth (AIG) 
and invasion through a reconstituted matrix. Conversely, stable overexpression of 
HK2 increased lactate production, cell proliferation, AIG and invasion. Pharmacologic 
inhibition of lactate production reduced the HK2-driven increase in invasion while 
addition of extracellular lactate enhanced invasion, together providing a link between 
glycolytic activity and metastatic potential. Stable knockdown of HK2 decreased 
primary tumor growth in cell line xenografts and decreased incidence of lung 
metastasis after tail vein injection. Gene expression analysis of tumors with decreased 
HK2 expression showed alterations in VEGF-A signaling, a pathway important for 
angiogenesis and metastasis, consistent with a requirement of HK2 in promoting 
metastasis. Overall our data provides strong evidence for the role of HK2 in promoting 
PDAC disease progression, suggesting that direct inhibition of HK2 may be a promising 
approach in the clinic.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a 
highly lethal malignancy with a five-year overall survival 
of <6% [1]. Over half of all patients initially present with 
metastatic disease, where treatment options are limited to 
cytotoxic chemotherapies that are not well tolerated and 
provide modest improvements in overall survival [2]. 
Over 90% of PDAC tumors contain activating mutations 
in the oncogene KRAS, suggesting that it may be an ideal 
target for therapy [3]. While knockdown of KRAS inhibits 
PDAC cell growth in vitro, direct targeting of KRAS and 
its main effector pathways have proven unsuccessful in 
the clinic [3, 4]. Much work has focused on identifying 
additional pathways promoting KRAS driven tumor 
growth in PDAC, with the hope of identifying new targets 
for therapy.
The importance of glucose metabolism in 
KRAS driven oncogenesis is well recognized [4–7]. 
In a genetically engineered mouse model (GEMM) of 
PDAC, oncogenic Kras activity promoted transcriptional 
upregulation of key enzymes involved in glucose 
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processing, including those regulating glycolysis, 
hexosamine biosynthesis and the pentose phosphate 
pathway [8]. Activity of these enzymes was required for 
tumor growth, suggesting a role for targeting glucose 
uptake and anabolism in PDAC [8]. Hexokinase 2 (HK2) 
is an enzyme responsible for phosphorylating glucose, 
a reaction necessary for glucose processing [9, 10]. 
Four hexokinase isoforms (HK1-HK4) are expressed 
at varying levels in tissues, but HK2 is the sole isoform 
overexpressed in cancer [11–15]. Genetic deletion of 
Hk2 caused a decrease in tumor burden and increased 
overall survival of Kras-driven lung and ErbB2-driven 
breast cancer GEMMS [12]. In addition, HK2 knockdown 
has been found to successfully inhibit tumor growth in 
glioblastoma, medulloblastoma and renal cell carcinoma 
[16–18].
While a direct role for HK2 in PDAC has yet to be 
reported, studies examining gene expression and PDAC 
patient outcomes have shown an association between 
increased expression of HK2 and more aggressive disease 
[19] [20]. Anabolic glucose metabolism promoted disease 
progression in a PDAC GEMM, however analysis of 
human tissue revealed increased expression of genes 
involved in aerobic glycolysis, including HK2, in 
primary PDAC and PDAC metastases without changes in 
expression of anabolic genes, suggesting that glycolysis 
may be important in human disease [20]. PDAC cell 
lines with elevated rates of glycolysis showed increase 
expression of an epithelial-mesenchymal transition 
(EMT) gene signature and were classified as a quasi-
mesenchymal, a PDAC subtype previously associated 
with shorter overall survival [21–23]. Taken together 
these studies provide strong, indirect evidence suggesting 
a role for HK2 and glycolysis in promoting PDAC disease 
progression.
The current study shows that HK2 is required 
for primary tumor growth and metastasis in PDAC. By 
overexpressing HK2 in PDAC cell lines, we show that 
increased levels of HK2 are sufficient to promote cell 
proliferation, anchorage independent growth (AIG) 
and invasion, supporting a role for HK2 in driving 
disease progression. Pharmacologic inhibition of lactate 
production dampens the effects of HK2 on invasion while 
increased extracellular lactate is sufficient to promote 
invasion. Overall, this study provides a mechanistic link 
between HK2 and metastasis via regulation of lactate 
production and suggests that direct inhibition of HK2 may 
be a promising approach for treating PDAC.
RESULTS
Genes involved in glucose uptake and glycolysis 
are dysregulated in PDAC
We examined the expression of genes involved 
with glucose metabolism using a previously described 
dataset of tumors from primary and metastatic sites of 143 
PDAC patients (GSE 71729) [24]. A list of 153 unique 
genes of interest was compiled using existing KEGG and 
Reactome gene lists for glucose metabolism, glycolysis 
and gluconeogenesis, the pentose phosphate pathway and 
O-glycan biosynthesis (Supplementary Table S1) [25]. Also 
included were 14 genes belonging to the family of sugar 
transport facilitators (SLC2A/GLUT) that are responsible 
for glucose uptake [26]. To identify genes associated with 
tumorigenesis, we looked for those highly expressed in 
primary tumors compared to unmatched normal pancreas. 
To identify genes associated with metastasis, we looked for 
genes highly expressed in metastases compared to primary 
tumors.
Four genes – glucose transporter 1 (GLUT1), HK2, 
lactate dehydrogenase A (LDHA), and triosephosphate 
isomerase 1 (TPI1) – were upregulated in primary tumors 
compared to normal pancreas and in metastases compared 
to primary tumors (P<0.001, Figure 1a, Supplementary 
Figure S1). GLUT1 and HK2 both play a role in glucose 
uptake. LDHA is a key enzyme responsible for producing 
lactate from pyruvate, the final step in aerobic glycolysis [27, 
28]. GLUT1, HK2, and LDHA were previously found to be 
regulated in an oncogenic Kras dependent manner, suggesting 
that they may be important for KRAS-driven tumor growth 
[8]. TPI1 catalyzes an isomerization reaction in the glycolytic 
cascade but is not regulated in a Kras-dependent manner and 
was, therefore, not further studied [8].
Increased HK2 expression is associated with 
poor patient survival after surgery
Increasing expression of key enzymes regulating 
glucose uptake and glycolysis in primary tumors and 
metastases suggest that these pathways are associated 
with aggressive tumor biology. To determine if GLUT1, 
LDHA, or HK2 was associated with clinical outcome, we 
evaluated the relationship between gene expression and 
patient survival (Figure 1). Patients with tumors containing 
high HK2 expression had a median survival of 13 months 
while patients with tumors containing low HK2 expression 
had a median survival of 21 months (P=0.027, Figure 1b). 
HK2 was also associated with shorter overall survival in 
patients with localized tumors who underwent curative 
surgery (hazard ratio (HR) 1.31 (1.07, 1.60), Figure 1c), 
suggesting that high HK2 expression may be associated 
with early disease relapse and metastasis. Neither GLUT1 
nor LDHA expression was associated with patient survival 
(Figure 1c).
HK2 is necessary for AIG and invasion in PDAC 
cell lines
To directly assess the requirement of HK2 for 
promoting tumor growth and invasion, si- and shRNA 
were used to transiently and stably knockdown HK2 in 
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two PDAC cell lines, CFPAC-1-LUC and PANC-1 (Figure 
2a). Both lines contain activating mutations in KRAS and 
exhibit the highest levels of HK2 expression relative to 
the normal immortalized epithelial cell line HPNE across 
a panel of PDAC cell lines (P<0.001, Figure 1d). Levels of 
HK1 were unaffected by transient and stable knockdown 
of HK2, suggesting that our constructs were HK2 specific 
and that there was no compensatory increase in HK1 
expression (Figure 2a).
To examine the effect of HK2 knockdown on PDAC 
cell growth, a soft agar assay was used to assess for AIG, 
a phenotype associated with both tumor growth and 
metastatic potential [29] (Figure 2b). Transient knockdown 
of HK2 in the CFPAC-1-LUC cell line caused a 72.7% 
decrease in colony growth compared to that observed for 
the nonspecific (NS) control (P<0.001, Figure 2c). Similar 
findings were observed with stable knockdown of HK2 
(P<0.030, Figure 2c). Transient and stable knockdown in 
PANC-1 with siHK2 and shHK2#1 resulted in an 82.0% 
and 71.0% decrease in colony growth relative to NS, 
respectively (P<0.001, Figure 2c). Stable knockdown 
using shHK2#2 caused 30.1% growth inhibition relative 
to shNS (P=0.06, Figure 2c). The dampened effect on 
colony growth may be explained by inefficient knockdown 
of HK2 with the shHK2#2 construct (Figure 2a). 
We hypothesize that the decrease in AIG observed 
results from a decrease in cell proliferation with HK2 
knockdown, as decreased anchorage dependent growth 
was observed in both cell lines with transient and stable 
knockdown of HK2 using a MTT assay (Supplementary 
Figure S2). To assess the effect of HK2 knockdown on 
invasion, a Matrigel coated transwell invasion assay was 
used (Figure 2d). Transient and stable knockdown of HK2 
caused an approximate 50% decrease in invasion in both 
cell lines (P<0.030, Figure 2e). These results show that 
HK2 is required for PDAC AIG and invasion.
Figure 1: HK2 expression is upregulated in PDAC and associated with a poor overall survival. a. Log
2
 expression of 
HK2 in normal pancreas, primary PDAC, and PDAC metastases. Box shows median expression with upper and lower quartiles and 
whiskers show maximum and minimum values. A one-way ANOVA with Bonferroni correction for multiple comparisons test determined 
statistical significance. b. Groups for Kaplan Meier survival analysis were based off HK2 expression in primary tumors. Lowest quartile 
showed median survival of 24 months (95% CI [14, 34]) while highest quartile showed median survival of 10 months (95% CI [9, 11]). c. 
Correlation between HK2, GLUT1 and LDHA expression in primary tumors (n=125) and overall survival as determined by univariate Cox 
proportional regression. Hazard ratios and 95% CI shown. d. Fold change in HK2 expression across a panel of PDAC cell lines relative 
to the immortalized epithelial cell line HPNE. Fold change determined using the ΔΔCT method with mean and standard error of the mean 
(SEM) shown (n=3 technical replicates).
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HK2 is sufficient to promote AIG and invasion in 
PDAC cell lines
HK2 expression is limited in most normal tissues 
but preferentially upregulated in cancer cells [11]. 
Whether HK2 is sufficient to promote PDAC growth and 
metastasis is unknown. To examine this, two PDAC cell 
lines stably overexpressing HK2 cDNA were generated 
(CFPAC-1-HK2 and PANC-1-HK2, Figure 3). Hexokinase 
(HK) activity was measured to confirm that stable HK2 
Figure 2: HK2 is required for AIG and invasion in PDAC cell lines. a. Transient and stable knockdown of HK2 was achieved 
using siRNA (siHK2, 20 nM) and a doxycycline inducible lentiviral shRNA construct (shHK2# and #2) in CFPAC-1-LUC and PANC-1. 
Cells were isolated after 72 hours of doxycycline (2 µg/mL) exposure. b. Representative images of colony formation in soft agar assays. 
c. Percent of growth with HK2 knockdown relative to control (siNS or shNS). Mean ± SEM of biological replicates (n=4) shown with 
student’s t-tests for statistical significance. d. Representative images from Matrigel coated transwell invasion assays. e. Percent invasion of 
HK2 knockdown relative to control (siNS or shNS). Mean ± SEM of biological replicates (n=6) shown with student’s t-tests for statistical 
significance.
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overexpression resulted in increased protein function. A 
3.3-fold increase in HK activity was observed in CFPAC-
1-HK2 and a 1.4-fold increase was observed for PANC-
1-HK2 (P<0.001, Figure 3b). Additionally transient 
knockdown of HK2 with siRNA caused a significant 
decrease in HK when compared to the control (P<0.010, 
Figure 3b). No change in HK1 expression was found in 
the cell lines generated, suggesting that the increased HK 
activity can be solely attributed to changes in the level of 
HK2.
We next determined the effects of HK2 
overexpression on AIG and invasion. A 5.1-fold increase 
in colony growth was observed with stable HK2 
overexpression relative to the GFP control in CFPAC-1-
HK2, while a 1.7-fold increase was observed in PANC-
1-HK2 (P=0.020, Figure 3d). We hypothesized that this 
increase in AIG results from an increased rate of cell 
proliferation, as HK2 overexpression caused an increase 
in anchorage dependent growth (Figure 3c). A 3.4-fold 
increase in invasion was observed for CFPAC-1-HK2 
relative to the control while a 2.4-fold increase was 
observed for PANC-1-HK2 (P<0.002, Figure 3e). Our 
data suggests that increased HK2 expression is sufficient 
to promote anchorage dependent and independent growth, 
as well as invasion.
HK2 promotes invasion by regulating lactate 
production
We hypothesized that the HK2-driven changes 
in invasion observed result from changes in glycolysis, 
as elevated glycolysis has been previously linked to 
metastasis [21, 22]. To this end, we measured lactate 
production in cell lines with transient knockdown and 
stable overexpression of HK2. “To ensure that changes 
in lactate production were a result of changes in the 
levels of HK2 and not a change in growth rate for the 
different experimental conditions examined, we measured 
lactate production over 24 hours after seeding an equal 
number of cells into the assay. At this time point no 
Figure 3: HK2 is sufficient to promote AIG and invasion in PDAC cell lines. a. Stable overexpression of HK2 (pHAGE HK2) 
relative to control (pHAGE GFP) in CFPAC-1 and PANC-1 cell lines. b. Percent hexokinase activity of knockdown (siNS vs. siHK2) 
and overexpression (pHAGE GFP vs. pHAGE HK2) cell lines relative to control. Mean ± SEM of biological replicates (n=3) shown with 
student’s t-tests for statistical significance. c. Cell proliferation in CFPAC-1-GFP and CFPAC-1-HK2 as determined using a MTT assay. 
Mean ± SEM of technical replicates (n=4) shown with student’s t-tests for statistical significance at 48, 72, and 96 hours of growth. d. 
Percent colony growth with HK2 overexpression relative to control. Mean ± SEM of biological replicates (n=3) shown with student’s t-tests 
for statistical significance. e. Percent invasion with HK2 overexpression relative to control. Mean ± SEM of biological replicates (n=6) 
shown with student’s t-tests for statistical significance.
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changes in proliferation or cell densities were observed 
(Supplementary Figure S2 and Figure 3c). An approximate 
20% decrease in lactate production was observed with 
HK2 knockdown relative to the NS control (P<0.003, 
Figure 4a). Conversely, stable HK2 overexpression 
produced a 1.3-fold and 1.2-fold increase in lactate 
production for the CFPAC-1-HK2 and PANC-1-HK2 cell 
lines, respectively, suggesting that changes in HK2 are 
sufficient to alter glycolysis in PDAC cell lines (P<0.003, 
Figure 4a). To determine if HK2 promotes invasion in a 
lactate dependent manner, the pharmacologic inhibitor 
oxamate, a structural analog of pyruvate, was used to 
inhibit glycolysis in cells with stable HK2 overexpression. 
Cells were pretreated with oxamate at the calculated IC50 
prior to seeding into transwell invasion assay (Figure 4b). 
At the time of seeding, a 3.2 and 4.1-fold decrease in 
lactate production was observed with oxamate treatment 
in CFPAC-1-HK2 and PANC-1-HK2, respectively, 
confirming inhibition of glycolysis relative to control 
(P<0.001, Figure 4c). An approximate 2.0-fold decrease 
in invasion was observed in oxamate treated cells with 
stable overexpression of HK2, suggesting that glycolysis 
is required for HK2 to promote invasion (P<0.010, Figure 
4d). We next determined if the addition of extracellular 
lactate was sufficient to promote invasion. Cells were 
incubated with media supplemented with lactate (40 mM) 
for 24 hours, conditions that induce changes in histone 
acetylation and gene expression [30]. The addition of 
lactate was sufficient to promote invasion in both cell 
lines, as a 3.5-fold increase in invasion for CFPAC-
1-HK2 and 2.5-fold increase in invasion of PANC-1-
HK2 were observed (P<0.001, Figure 4e). These results 
suggest that HK2 regulates invasion in a lactate-dependent 
manner, supporting a direct link between elevated rates of 
glycolysis and increased metastatic potential.
Figure 4: HK2 regulates lactate production and invasion in PDAC cell lines. a. Relative lactate production in CFPAC-1 
and PANC-1 with HK2 knockdown (siHK2 vs. siNS) and overexpression (pHAGE HK2 vs. pHAGE GFP). Mean ± SEM of biological 
replicates (n=3) shown with student’s t-tests for statistical significance. b. IC50 determination for CFPAC-1-HK2 and PANC-1-HK2 after 
72 hours of oxamate treatment; Mean ± SEM of technical replicates (n=4) shown with student’s t-tests for statistical significance. CFAPC-1 
IC50 calculated to be 15 mM while PANC-1 determined to be 16mM using GraphPad Prism software (v.5, GraphPad Software, INC. La 
Jolla, CA, USA). c. L-lactate produced (mM) in CFPAC-1-HK2 and PANC-1-HK2 cell lines treated with PBS or IC50 oxamate for 72 
hours. Mean ± SEM of biological replicates (n=3) shown with student’s t-tests for statistical significance. d. Percent invasion in cells treated 
with PBS or IC50 oxamate. Mean ± SEM of biological replicates (n=6) shown with student’s t-tests for statistical significance. e. Percent 
invasion in PDAC cells incubated with extracellular lactate (40 mM). Mean ± SEM of biological replicates (n=6) shown with student’s 
t-tests for statistical significance.
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HK2 is necessary for PDAC tumor growth and 
promotes changes in gene expression in vivo
To examine the effects of HK2 knockdown 
on primary tumor growth, CFPAC-1-LUC cells 
containing a doxycycline-inducible shHK2#1 or shNS 
(control) were subcutaneously injected into immune-
compromised mice. HK2 knockdown was confirmed 
in tumors expressing the shHK2#1 compared to those 
expressing shNS after 3 and 7 days of doxycycline 
administration (Figure 5a). To assess the effect of HK2 
knockdown on long-term tumor growth, mice were 
given doxycycline or sucrose (control) once tumors 
reached an average volume of 152 mm3 (standard 
deviation (SD) 46 mm3). No change in growth was 
observed in the shNS tumors in mice treated with 
doxycycline, confirming that administration of 
doxycycline alone had no effect on tumor growth 
(Figure 5b). However, induction of shHK2#1 
expression resulted in tumor growth inhibition during 
the 30 day treatment period compared to the shNS 
controls (P<0.030, Figure 5c). At the end of treatment 
Figure 5: HK2 is required for PDAC primary tumor growth and regulates gene expression. a. Expression of HK2 in 
CFPAC-1-LUC tumors containing doxycycline inducible shNS or shHK2#1 treated with sucrose (control) or doxycycline for 3 or 7 days. 
b. Percent tumor volume relative to start of treatment for shNS tumors treated with sucrose (black, n=9) or doxycycline (grey, n=10) for 
30 days. Average normalized tumor volume and SEM shown. c. Percent tumor volume relative to start of treatment for shHK2 tumors 
treated with sucrose (black, n=8) or doxycycline (grey, n=8) for 30 days. Average normalized tumor volume and SEM shown with student’s 
t-tests for statistical significance at each time point. d. Representative images of tumors isolated after 30 days of treatment with sucrose or 
doxycycline. e. Heat map of the expression of the top 20 ranked genes from the gene lists by Schoenfeld, et al [25] [32], including HK2 and 
VEGF-A, for shNS (control) and shHK2#1 (HK2 knockdown) tumors isolated at the end of treatment as determined by RNA-sequencing.
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an average reduction in tumor volume of 57.5% was 
observed with HK2 knockdown (P=0.020, Figure 5d).
RNA sequencing was performed on tumors 
harvested at the end of the study to determine the effect 
of HK2 knockdown on gene expression in vivo. Genes 
whose average reads per kilo base of transcript per 
million mapped reads (RPKM) was <10 were excluded 
from analysis, so that only genes with a high level of 
baseline expression were included (Supplementary 
Table S2, n=6,120). Gene set enrichment analysis 
(GSEA) [25] was performed to identify differentially 
regulated gene sets between control (shNS, n=3) and 
HK2 knockdown (shHK2#1,n=4), with a focus on gene 
sets contained in the molecular signature database’s 
(MSigDBv5) hallmark and oncogenic signatures gene 
lists [25]. We found 27 gene sets to be significantly 
enriched in shNS tumors relative to shHK2 tumors 
(Supplementary Table S3, P<0.02, false discovery 
rate (FDR)<0.100) and 18 gene sets significantly 
enriched with HK2 knockdown relative to shNS 
(Supplementary Table S4, P<0.02, FDR<0.100) [25]. 
Interestingly, one of the highest enriched pathways 
in the control tumors included genes upregulated 
with increased vascular endothelial growth factor-A 
(VEGF-A) activity (VEGF_A_UP.VI_UP, normalized 
enrichment score (NES) 2.2, P<0.001, FDR<0.001, 
Figure 5e), a pathway important for promoting 
metastasis [31, 32]. Furthermore, genes downregulated 
with VEGF-A signaling were enriched in the HK2 
knockdown tumors (VEGF_A_UP.VI_DN, NES 
-2.4, P<0.001, FDR<0.001, Figure 5e), suggesting 
that HK2 knockdown is associated with inhibition 
of VEGF-A signaling [32]. To validate the findings 
observed by RNA-sequencing, we examined the 
expression integrin β4, one gene known to regulated in 
a VEGF-A dependent manner [32], in tumors with HK2 
knockdown (Supplementary Figure S3). We observed 
a decrease in total integrin β4 expression with HK2 
knockdown, further supporting a link between VEGF-A 
signaling and HK2 expression.
HK2 is required for PDAC metastasis in vivo
To examine the requirement of HK2 for the 
promotion of metastasis, a tail vein assay was used 
[33]. CFPAC-1-LUC cells containing inducible shRNA 
constructs were treated with doxycycline prior to tail 
vein injection to induce shRNA expression (Figure 2a). 
Bioluminescence was used to monitor development 
of lung metastases and quantify tumor growth (Figure 
6a). The average bioluminescence measured in the 
lungs of shNS injected mice was approximately 100-
fold higher than that observed for the shHK2#1 injected 
mice (P=0.001, Figure 6b). The presence of metastatic 
disease was observed in 7 out of 7 mice injected with the 
shNS control compared to 3 out of 9 mice injected with 
shHK2#1 cells (P=0.011, Figure 6c). The presence of 
metastatic tumors was confirmed using hematoxylin and 
eosin (H&E) staining of sectioned lung tissue obtained 
from mice injected with shNS (Figure 6d, top row). No 
histological evidence of tumor formation was observed 
with injection of HK2 knockdown cells (Figure 6d, bottom 
row). These results show a requirement for HK2 in the 
extravasation and survival of cancer cells at distant organ 
sites, confirming an important role for HK2 in promoting 
metastasis.
DISCUSSION
PDAC is a highly lethal disease with an increased 
incidence of metastasis and an overall poor prognosis 
[2]. Similar to a GEMM which showed genes regulating 
glucose metabolism to be upregulated in PDAC [8], 
we saw increased expression of key glycolytic genes, 
including GLUT1, HK2 and LDHA, in primary PDAC 
tumors relative to normal pancreas, suggesting a role 
for these genes in human tumorigenesis. We show 
that knockdown of HK2 results in decreased PDAC 
growth in vitro and in vivo, in agreement with what 
has been observed in other cancers [12, 16–18]. 
HK2 regulates glucose uptake, a process upstream of 
metabolic pathways including glycolysis, hexosamine 
biosynthesis, the pentose phosphate pathway and the 
citric acid cycle [4, 8]. Direct targeting of HK2 can, 
therefore, impede the flow of glucose into multiple 
downstream pathways necessary for KRAS driven 
tumor growth [8, 21]. Genetic deletion of HK2 in 
a preclinical model of Kras driven lung cancer was 
sufficient to alter glucose metabolism and improve 
overall survival [12], suggesting that direct targeting of 
HK2 would be beneficial in PDAC.
We also show that increased expression of HK2 
in primary tumors is associated with shorter overall 
survival in PDAC patients undergoing curative surgery, 
in agreement with a smaller study that correlated 
increased HK2 protein expression with worse PDAC 
patient outcomes [19]. This, along with the observation 
that HK2 is upregulated in PDAC metastases relative 
to primary tumors, supports a role for HK2 in the 
metastatic process. Associations between increased 
HK2 expression, metastatic disease, and poor clinical 
outcomes have been observed in other cancers however 
a direct link between HK2 and metastasis has not been 
shown [19, 34, 35].
Here we provide direct evidence that HK2 is 
necessary and sufficient to promote metastasis in PDAC, 
as its increased expression promotes invasion and 
its knockdown inhibits cancer cell extravasation and 
colonization at distant organ sites, important components 
of the metastatic cascade [31, 36]. A study of PDAC 
cell lines correlated increased rates of glycolysis with 
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aggressive tumor biology, suggesting that glycolysis may 
be important for metastasis [21]. We found that HK2 
directly promotes metastasis via regulation of glycolysis, 
as pharmacologic inhibition of lactate production prevents 
HK2-driven invasion and extracellular lactate is sufficient 
to enhance invasion. This result is in agreement with 
previous studies showing extracellular lactate enhances 
migration of breast cancer cell lines, encourages 
metastases seeding of breast cancer cell lines in vivo and 
promotes motility of glioblastoma cell lines [37, 38]. As 
increased lactate production has also been linked to poor 
patient outcomes [21, 37, 39, 40]] we suggest that direct 
targeting of HK2 or inhibition of glycolysis may improve 
patient outcomes by limiting the formation of metastases.
Increased rates of glycolysis can promote invasion 
by altering the pH of the tumor microenvironment, 
enhancing cell signaling, influencing matrix 
metalloprotease activity and regulating gene 
expression [30, 37, 38, 41–43]. We show that genes 
involved in VEGF-A signaling, a pathway important 
for angiogenesis and metastasis [31], are significantly 
altered by HK2 knockdown. While a direct link between 
HK2 and VEGF-A was not assessed here, others have 
shown that lactate production influences VEGF-A 
signaling [42, 44, 45]. We show that extracellular 
lactate enhances PDAC cell invasion when present at 
concentrations known to influence gene expression [30]. 
We hypothesize that HK2 regulates lactate production 
and this, in turn, promotes VEGF-A signaling and 
changes in gene expression necessary for metastasis. 
While our data supports this hypothesis, more studies 
Figure 6: HK2 is required for metastasis in PDAC. a. Bioluminescence of mice injected with CFPAC-1-LUC shNS cells (top 
row) and cells with HK2 knockdown (CFPAC-1-shHK2 #1, bottom row) at the start of the study (column one) and at the end of the 
study (column 3). b. Bioluminescence measured for tumors observed in lungs obtained after autopsy. Each point represents luminescence 
of tumor foci (shNS, n=7 and shHK2, n=3) or an entire lung if no foci were observed (shHK2, n=6). c. Fisher’s exact t-test showing a 
significant difference in formation of metastases with HK2 knockdown (P=0.011). d. Representative ex vivo images used for quantification 
of bioluminescence. H&E staining was used to confirm metastases formation. Arrowheads point to cancer cells in a metastatic lesion with 
surrounding normal lung tissue (top row). Lungs that did not exhibit bioluminescence showed no histological evidence of metastases 
(bottom row).
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are needed to confirm the connection between HK2 and 
VEGF-A.
In conclusion the present study supports a 
requirement for HK2 in PDAC tumorigenesis and 
metastasis that helps explain the associated findings of 
high HK2 expression in PDAC patients with metastatic 
disease. We show that HK2 influences the invasive 
potential of PDAC cells by directly regulating glycolysis 
and that its knockdown induces changes in gene expression 
of pathways important for promoting metastasis, including 
VEGF-A signaling. Our data suggests that the targeting of 
HK2 may be a promising approach for treating metastatic 
PDAC.
MATERIALS AND METHODS
Cell culture and stable cell line generation
Human cell lines CFPAC-1, HPAF-II, Hs 766T, 
T3M4, and PANC-1 were obtained from the American 
Type Culture Collection and authenticated via short–
tandem repeat profiling (Genetica, Burlington, NC, 
USA). The HPNE cell line was described previously [46]. 
CFPAC-1 was cultured in RPMI 1640, CFPAC-1-LUC 
(pLENTI-CMV-Luciferase) was cultured in RPMI 1640 
with geneticin (500 µg/mL, Invitrogen, Grand Island, 
NY, USA), and PANC-1 was cultured in DMEM. All 
were supplemented with 10% fetal bovine serum (FBS, 
Invitrogen) and penicillin/streptomycin (Invitrogen) 
and incubated at 37 °C in 5% CO2 atmosphere. For 
HK2 overexpression, the HK2 cDNA sequence from the 
pDONR-223-HK2 donor vector [47] (Addgene #23854) 
was cloned into a pHAGE puro destination vector 
(donated by the laboratory of William Kim, MD) using 
LR-clonase reaction as per the manufacturer’s instructions 
(ThermoFisher Scientific #11791, Grand Island, NY, USA). 
For HK2 knockdown cell lines, shRNA sequences (below) 
were cloned into the pTRIPZ plasmid using EcoR1 and 
Xho1 restriction enzyme digestion of the pTRIPZ-shNS 
vector (donated by the laboratory of Channing Der, PhD). 
All constructs were verified by Sanger sequencing (Eton 
Biosciences, Research Triangle Park, NC, USA).
shHK2#1: CCGTAACATTCTCATCGATTT
shHK2#2: GCTACAAATCAAAGACAAGAA
A replication-incompetent lentivirus was generated 
in 293T cells using psPAX2 (Gag, Pol, Rev, Tat), pMD2.G 
(VSV-G), and target vector. For transduction, 1×106 cells 
were seeded in 100 mm plates with media containing 
lentivirus and polybrene (8 µg/mL, Invitrogen). After 24 
hours, infected cells were selected with puromycin (2 µg/mL, 
Invitrogen). To induce shRNA expression in pTRIPZ lines, 
cells were incubated for 72 hours with media containing 2 
µg/mL doxycycline (Sigma-Aldrich, St. Lois, MO, USA).
Transient knockdown with siRNA
Reverse transfection in a six-well plate was 
performed with Lipofectamine RNAiMax (Invitrogen) 
as per the manufacturer’s guidelines. 4-5x105 cells were 
seeded per well and a final concentration of 20 nM siNS 
(#4404021, ThermoFisher Scientific) or siHK2 (Catalog 
#S6560, Applied Biosystems, Grand Island, NY, USA) 
was used. Cells were incubated for 48 hours prior to use 
in assay or western blot.
Western blot
Samples were lysed in 200 μL RIPA buffer (pH 7.4) 
containing protease inhibitors (ThermoFisher Scientific). 
20-25 µg protein suspended in SDS loading buffer was run 
on 10% SDS polyacrylamide gels and electrotransferred 
to PVDF membranes. Membranes were blocked in 5% 
milk and incubated with 1:1,000 dilutions of primary 
antibodies in 5% BSA, including anti-HK1 (sc-#46695, 
Santa Cruz Biotechnology, Dallas, TX, USA), anti-HK2 
(Catalog #2867, Cell Signaling Technology, Danvers, MA, 
USA), anti-integrin β4 (Cell Signaling Technology, Cat# 
4707) and the loading controls anti-β-Actin (sc-#47778, 
Santa Cruz Biotechnology) and anti-vinculin (Catalog 
#V9131, Sigma). Membranes were incubated with 1: 5000 
dilutions of appropriate secondary antibodies in 5% milk 
(ThermoFisher Scientific). Incubations were for 1 hour at 
room temperature and Clarity Western ECL substrate with 
ChemiDoc XRS+ imaging system (Bio-Rad Laboratories, 
Hercules, CA, USA) were used to detect immunoreactive 
bands.
AIG
1-2 x104 cells were seeded into a soft agar assay 
as was previously outlined in Martin et al [48]. Briefly a 
six well plate was coated with 2 mL of a 0.6% bacto-agar 
and culture medium mixture. 500 µL of a cell and 0.4% 
bacto-agar mixture was added after solidification of the 
first layer. 300 µL media was added every four days for 
two-three weeks. If cells were treated with doxycycline 
prior to seeding, administration of media with doxycycline 
(2 µg/mL) continued. Colony growth was using Image 
J software (NIH, Bethesda, Maryland, USA). Percent 
growth was calculated by dividing the number of colonies 
observed by the average number of colonies in the 
corresponding control.
Transwell invasion
Uncoated inserts with 8-µm pores (Catalog #82050, 
Greiner Bio-One, Monroe, NC, USA) were coated with 
100 µL of a diluted growth factor reduced Matrigel 
membrane matrix (300 µg/mL, ThermoFisher Scientific) 
and incubated at 37 oC for 2 hours. Coated inserts were 
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then placed into a 24 well plate containing 750 µL normal 
culture media. 1-2 x105 cells were suspended in 250 µL 
media supplemented with 1% FBS and seeded into the 
upper chamber of insert. Cells invaded for 16 hours. 
Inserts were then cleaned, fixed, and stained with Diff 
Quik as per manufacturer’s instructions (ThermoFisher 
Scientific). The number of cells invading was determined 
by counting five random fields per insert (counted by a 
blinded second party). Percent invasion was calculated by 
dividing the total number of cells invaded by the average 
number of cells invaded for the appropriate control.
Hexokinase activity and lactate production
To examine hexokinase activity a colorimetric 
assay was performed as per manufacturer’s instructions 
(Hexokinase activity kit, Catalog #MAK091, Sigma). 
Sample preparation included lysis of 1x106 cells in assay 
buffer, with a 1:10 dilution of lysate used in assay. A 
glycolysis cell-based assay was performed to measure 
l-lactate production as per manufacturer’s instructions 
(Catalog #600450, Caymen Chemical, Ann Arbor, MI, 
USA). 1x104 cells in 200 µL were seeded per well in a 
96-well plate for 24 hours. 20 µL of medium was collected 
into a new 96 well plate for colorimetric detection. 
Absorbance at appropriate wavelengths was measured 
with a Synergy 2 microplate reader (BioTek, Winooski, 
VT, USA). Percent hexokinase activity and lactate 
production were determined by dividing the corrected 
absorbance reading for each replicate by the average 
corrected absorbance for the appropriate control.
Cell proliferation
To examine cell proliferation, 1x103 cells in 200 
µl were plated in quadruplicate into 96-well plates. 
After 24, 48, 72, or 96 hours of growth, 50 μl of 5 mg/
mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) dissolved in PBS was added to each well. 
After 30 minutes the mixture was aspirated and 200 µl of 
dimethyl sulfoxide (DMSO) was added to each well and 
mixed thoroughly. A
560nm
 was measured using a Synergy 
2 microplate reader (BioTek). For IC50 determination 
1x103 cells in 200 µl were plated in quadruplicate into 96-
well plates. After 24 hours, the medium was replaced with 
medium containing 75 mM PBS or oxamate (75 mM to 
0.1 mM, Sigma). After 72 hour incubation, 50 μl MTT 
was added to each well and incubated for 30 minutes. The 
mixture was aspirated and 200 µl of DMSO was added 
to each well, mixed thoroughly, and A
560 nm
 was measured 
using a Synergy 2 microplate reader. The IC50 was 
calculated using GraphPad Prism software (v5, GraphPad 
Software, INC. La Jolla, CA, USA).
Gene expression
qPCR
RNA was isolated from CFPAC-1, HPNE, HPAF-
II, Hs 766T, T3M4, and PANC-1 cell pellets using an 
RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). 
2 µg of RNA was used for cDNA synthesis (Applied 
Biosystems) and 50 ng of RNA was used for real-time 
PCR (Applied Biosystems). Reactions were performed 
in triplicate on a 384 well plate using standard PCR 
settings on a QuantStudio 6 Flex Real-Time PCR 
system (Applied Biosystems). HK2 expression was 
assessed with HK2 TaqMan qPCR array (Applied 
Biosystems, Hs00606086_m1) while β-actin was 
assessed with ACTB TaqMan qPCR array (Applied 
Biosystems, Hs01060665_g1). The ΔΔCT method was 
used for analysis.
RNA sequencing
200-1000 ng of total RNA was used to prepare 
libraries with the TruSeq Stranded mRNA Sample Prep Kit 
(Illumina, San Diego, CA, USA). 75 bp paired-end reads 
were sequenced on a NextSeq 500 Desktop Sequencer 
using a high output flow cell kit (Illumina). Reads were 
separated by species of origin using Xenome [49]. Human 
specific reads were then aligned and quantified using 
Tophat2 [50], Cufflinks [51], hg19, mm10, and the UCSC 
transcript and gene definitions (genome.ucsc.edu). mRNA 
gene expression was analyzed with javaGSEAv2.2.1, and 
MSigDBv5.0 [25].
Animal Studies
All mouse studies were completed under protocols 
approved by the University of North Carolina at Chapel 
Hill’s Institutional Animal Care and Use Committee.
Subcutaneous tumor injection
2x106 CFPAC-1-LUC shRNA cells were 
subcutaneously injected into the flanks of 6-8 week old 
female nu/nu mice. To limit variability in induction of 
shRNA expression between control and experimental 
cell lines, cells containing doxycycline-inducible shNS 
were injected into the right flank while shHK2#1 cells 
were injected into the left flank of the same mouse. When 
tumors grew to a mean of 152 mm3 (SD 45.5 mm3) mice 
were randomized and given either 2.5% sucrose or 2.5% 
sucrose + 1 mg/mL doxycycline in drinking water for 
the specified time period. Tumor volume was measured 
three times per week and calculated using the formula 
(length×width2)/2. Student’s t-tests compared the growth 
of treatment versus control during the study and a one-
way ANOVA with Bonferroni correction for multiple 
comparisons test determined statistical significance of 
final tumor volume.
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Tail vein injection
CFPAC-1-LUC shNS and CFPAC-1-LUC shHK2#1 
cells incubated with culture medium containing 2 µg/mL 
doxycycline for 72 hours prior to injection. Treatment 
continued via administration of a 2.5% sucrose + 1mg/
mL doxycycline throughout the study. 2x106 cells in 100 
µL PBS were injected into the tail veins of 6-8 week 
old female nu/nu mice as previously described in Elkin, 
et al [33]. Mice were monitored for lung metastases 
weekly after the initial injection using an IVIS Lumina 
Kinetic optical imaging system with an EMCCD camera 
(PerkinElmer, Waltham, MA, USA). Lungs were collected 
upon autopsy, fixed in 10% formalin, paraffin embedded 
(FFPE), and sectioned into 10 µM slices at 100 µM 
intervals and stained with H&E. Fisher’s exact t-test 
determined statistical significance.
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